Novartis, Bristol-Myers Squibb, Gilead Sciences, Sanofi... These multinational pharmaceutical companies released their financial reports in early February, announcing their 2021 results. After combing through the People's Daily health client, it was found that the global revenue of these multinational pharmaceutical companies rose as a whole, with an increase of 5%-11%, and the core varieties supported half of the rising performance.
Among them, the most eye-catching performance is AbbVie's core variety "adalimumab", the financial report shows that the product in 2021 global revenue of 20 billion US dollars, can be called "the king of single product sales".
Novartis: Two core varieties contribute 16% of global revenue
On February 7, Novartis Group announced its 2021 results, with full-year net sales revenue reaching US$51.626 billion, up 6% year-on-year. Among them, sales revenue in the Chinese market was US$3.052 billion, an increase of 18% year-on-year, accounting for 6% of Novartis' total global revenue.
Novartis' Innovative Pharmaceutical business is currently divided into two major business units, Novartis Oncology and Novartis Pharmaceuticals, with full-year sales revenue of $42 billion in 2021, an increase of 8% year-on-year. Novartis' current business units currently cover diseases including immunity, blood diseases, skin diseases, ophthalmology, nerve, respiratory, cardiovascular, renal and metabolic diseases, and other mature diseases.
In terms of specific varieties, Cosentyx (scuziyuzumab) and the new drug Enterto (sakuba tridan) contributed a total of 8.266 billion US dollars, becoming the most critical drug driving Novartis' performance growth.
Among them, in December 2021, Cosentyx was approved by the U.S. FDA for the treatment of active tendonitis-associated arthritis (ERA) in patients aged 4 years and older and active juvenile psoriatic arthritis (JPsA) in patients aged 2 years and older, becoming the only biologic agent approved in the United States for ERA and PsA in children and adolescents. Entresto's two indications for the treatment of HFrEF and hypertension are listed in the National Medicare Directory, effective from January 2022.
Bristol-Myers Squibb: Odivo generated $7.523 billion in full-year revenue
On February 4, Bristol-Myers Squibb announced its 2021 results, with total revenue of $46.385 billion, up 9% year-on-year.
The results of the 2021 financial report show that the core that currently brings significant growth momentum to Bristol-Myers Squibb is still the benchmark product Odivo (Navuliyuzumab). The first-line treatment of renal cell carcinoma, pleural mesothelioma and gastric cancer, Odivore has returned to growth momentum, with sales revenue of 7.523 billion US dollars in 2021, an increase of 8% year-on-year.
Sanofi: Dupridosuzumab sales revenue continues to grow
On February 4, Sanofi announced its 2021 results, with net income of 37.761 billion euros, an increase of 7.1% year-on-year.
Dupleliumab is Sanofi's current flagship product, with sales revenue up 52.7% year-on-year in 2021 and sales of €5,249 million. Its growth is due to the sustained release of demand from adults, adolescents, children aged 6-11 years with atopic dermatitis, as well as the expansion of labels and patient penetration on asthma, chronic rhino-sinusitis with nasal polyps indications.
In June 2020, it was approved for the treatment of moderate to severe atopic dermatitis in adults in China and was included in the 2020 edition of the National Medical Insurance Directory, covering more than 30,000 patients. In September 2021, it was approved to expand the use of atopic dermatitis in adolescents over 12 years old in China.
Abbvie: The adalimumab single category grossed more than $20 billion
AbbVie announced 2021 results, autoimmune disease business revenue of 25.284 billion US dollars, the share of 45%, of which, adalimumab in 2021 sales revenue of 20.694 billion US dollars, the annual sales of a single drug exceeded the 20 billion US dollar mark, while the follow-up autoimmune product line is also strongly supplemented, Resalizumab sales revenue of 2.939 billion US dollars, upatinib sales revenue of 1.65 billion US dollars, as a double insurance. AbbVie sees oncology as the second largest segment outside of autoimmune diseases, with Vinaikera's sales revenue reaching $1.82 billion in 2021, up 36.1% year-on-year.
Gilead Science: Remdesivir revenue nearly doubled
On February 1, Gilead Sciences announced its 2021 results, with total revenue of $27.305 billion for the full year, up 11% year-on-year. R&D investment was US$5.363 billion, an increase of 6.4% year-on-year.
In terms of business performance by disease area, HIV sales revenue declined to $16.3 billion ( -4 %). In terms of specific products, the new three-in-one HIV drug, Betoweg, is a core pillar of Gilead's product, with sales revenue of $8.624 billion in 2021, an increase of 19% year-on-year.
It is worth noting that the sales revenue of remdesivir sales increased by 98% in 2021 to reach $5.56 billion. However, 2021Q4 has already seen a significant decline from 2020Q4 (19.38 vs$1.357 billion). Cell therapy products have expanded steadily, and Yescarta has maintained steady growth, with sales revenue of $695 million in 2021, an increase of 23.6% year-on-year.
Editor-in-charge: Yan Feifei
Proofreader: Sun Baoguang